Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin

Journal of Cystic Fibrosis

Volumn 10, Issue 3, 2011, Pages 166-174

  Growcott, E J ^a   Coulthard, A ^a   Amison, R ^a   Hardaker, E L ^a   Saxena, V ^a   Malt, L ^a   Jones, P ^a   Grevot, A ^b   Poll, C ^a   Osborne, C ^a   Banner, K H ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Agar beads; Ciprofloxacin; Pseudomonas aeruginosa

Indexed keywords

AGAR; CIPROFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; INFLAMMATION; MALE; NEUTROPHILIA; NONHUMAN; PARTICLE SIZE; PSEUDOMONAS INFECTION; RAT; RESPIRATORY TRACT INFECTION;

ACUTE DISEASE; AGAR; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; HEXOSES; LEUKOCYTE COUNT; MALE; MICROSPHERES; NEUTROPHILS; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955957589     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.12.007     Document Type: Article

References (21)

1. Saadane A., Soltys J., Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-ΚB activation, cytokine secretion and persistent lung inflammation. J Allergy Clin Immunol 2006, 117:1163-11639.
2. Courtney J.M., Ennis M., Elborn J.S. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 2004, 3:223-231.
3. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Ghnaim H., Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995, 152(6 Pt1):2111-2118.
4. Cash H.A., Woods D.E., McCullough B., Johanson W.G., Bass J.A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 1979, 119:453-459.
5. Heeckeren A., Walenga R., Konstan M.W., Bonfield T., Davis P.B., Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997, 100(11):2810-2815.
6. Tsai W.C., Rodriguez M.L., Young K.S., Deng J.C., Thannickal V.J., Tateda K., et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004, 170:1331-1339.
7. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduced spontaneous and induced inflammation in {increment}F508 cystic fibrosis mice. Respir Res 2006, 7:134.
8. Pierre M., Husson M.-O., Le Berre R., Desseyn J.-L., Galabert C., Béghin L., et al. Omega-3 polyunsaturated fatty acids improve host response in chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1422-L1431.
9. Guilbault C., Saeed Z., Downey G.P., Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007, 36(1):1-7.
10. Cantin A., Woods D.E. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med 1999, 160:1130-1135.
11. Woods D.E., Cantin A., Cooley J., Kenney D.M., Remold-O'Donnell E. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 2005, 39:141-149.
12. Boyer S., Faure K., Ader F., Husson M.O., Kipnis E., Prangere T., et al. Chronic pneumonia with Pseudomonas aeruginosa and impaired alveolar fluid clearance. Respir Res 2005, 6:17-25.
13. Amano H., Oishi K., Sonoda F., Senba M., Wada A., Nakagwa H., et al. Role of cytokine-induced neutrophil chemoattractant-2 (CINC-2)α in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa. Cytokine 2000, 12(11):1662-1668.
14. Marier J.F., Brazier J.L., Lavigne J., Ducharme M.P. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003, 52:247-252.
15. Konstan M.W., Vargo K.M., Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Am Rev Respir Dis 1990, 141:186-192.
16. Taccetti G., Campana S., Festini F., Mascherini M., Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26:1-4.
17. Hansen C.R., Pressler T., Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15years experience. J Cyst Fibros 2008, 7:523-530.
18. Join-Lambert O.F., Michéa-Hamzehpour M., Köhler T., Chau F., Faurisson F., Dautrey S., et al. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Antimicrob Agents Chemother 2001, 45(2):571-576.
19. Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003, 3:359-371.
20. Huang H.-C., Shieh C.-C., Yu W.-L., Cheng K.-C., Chen C.-C., Chang S.-T., et al. Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. Respirology 2008, 13:47-52.
21. Grimwood K., To M., Rabin H.R., Woods D.E. Sub inhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model. J Antimicrob Chemother 1989, 24:937-945.